ERBB2 and breast cancer: Trastuzumab, a monoclonal antibody, is labeled with 89Zr for identification of BC cells that over-express the Her2 receptor, as in the case of HER2+ subtypes of BC and luminal B. 89Zr-trastuzumab is clinically used in the identification of HER2+ BC lesions.